Pregabalin Capsule
Product Images NDC 76420-119

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 76420-119). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin-100mg-1000-jpg (Pregabalin 100mg)

Labels for Pregabalin Capsule 100 mg oral capsules by Enovachem Pharmaceuticals, relabeled by same company in Torrance, CA. The labels indicate quantities of 30, 60, and 90 capsules, with NDC codes 76420-120-30, 76420-120-60, and 76420-120-90 respectively. Distributed by Rising Pharmaceuticals, Inc. The labels include barcode, storage instructions, and controlled substance status (CV).*

FDA Label Image

Pregabalin-150mg-1000-jpg (Pregabalin 150mg)

Three packaging labels for Pregabalin Capsule 150 mg from Enovachem Pharmaceuticals, relabeled and distributed by Rising Pharmaceuticals, Inc. Each label shows NDC numbers 76420-121-90, 76420-121-30, and 76420-121-60 respectively, quantities of 90, 30, and 60 capsules, along with storage instructions, package batch and lot placeholder details, and a QR code on each label.*

FDA Label Image

Pregabalin-200mg-1000-jpg (Pregabalin 200mg)

Packaging labels for Pregabalin Capsule 200 mg by Enovachem Pharmaceuticals, distributed by Rising Pharmaceuticals, Inc. Each label shows the quantity (30, 60, 90 capsules), NDC numbers (76420-122-30, 76420-122-60, 76420-122-90), orange opaque capsule description, storage instructions at 20-25°C, and a QR code. The label includes caution about prescription use and child safety.*

FDA Label Image

Pregabalin-225mg-1000-jpg (Pregabalin 225mg)

Labels for Pregabalin Capsule 225 mg, each labeled as packaged by Enovachem Pharmaceuticals, located in Torrance, CA. Each label indicates distribution by Rising Pharmaceuticals, Inc. The labels specify quantities of 90, 30, and 60 capsules respectively, with orange opaque/white opaque capsules described. Each includes an NDC number starting with 76420-123, a barcode, and standard federal law caution statements about prescription requirements and storage conditions.*

FDA Label Image

Pregabalin-25mg-1000-jpg (Pregabalin 25mg)

Packaging labels for Pregabalin Capsule 25 mg by Enovachem Pharmaceuticals showing three different quantities: 90 count (NDC 76420-117-90), 30 count (NDC 76420-117-30), and 60 count (NDC 76420-117-60). Labels include distributor information (Rising Pharmaceuticals, Inc.), white opaque capsule description, batch and lot placeholders, storage instructions, federal law dispensing warnings, and barcode.*

FDA Label Image

Pregabalin-300mg-1000-jpg (Pregabalin 300mg)

Pregabalin Capsule 300 mg packaging labels relabeled by Enovachem Pharmaceuticals, displaying three different package quantities: 90 capsules (NDC 76420-124-90), 30 capsules (NDC 76420-124-30), and 60 capsules (NDC 76420-124-60). Labels include distribution information indicating Rising Pharmaceuticals, Inc., details about capsule appearance (red opaque/white opaque), and drug status as CV. Each label also includes barcodes and regulatory caution statements.*

FDA Label Image

Pregabalin-50mg-1000-jpg (Pregabalin 50mg)

Three separate labels for Pregabalin Capsule 50 mg by Enovachem Pharmaceuticals, packaged in quantities of 90, 30, and 60 capsules. Each label includes NDC numbers 76420-118-90, 76420-118-30, and 76420-118-60 respectively, distributed by Rising Pharmaceuticals, Inc. Labels specify the capsules are white opaque with capsule/LA:42, and provide storage instructions and caution statements.*

FDA Label Image

Pregabalin-75mg-1000-jpg (Pregabalin 75mg)

Packaging labels for Pregabalin Capsule 75 mg by Enovachem Pharmaceuticals, relabeled by Rising Pharmaceuticals, Inc. The image shows three distinct labels indicating quantities of 90, 30, and 60 capsules, each with unique NDC codes (76420-119-90, 76420-119-30, 76420-119-60), including details about storage (20-25°C controlled room temperature), drug status (CV), and barcode and QR code on each label.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure diagram of Pregabalin, showing the molecular arrangement of its atoms including the amino group (NH2) and carboxyl group (CO2H).*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and adjustment factor for female patients is shown. This text panel appears to provide dosing or pharmacokinetic calculation information related to Pregabalin capsules by Asclemed USA, Inc.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and a placebo. The vertical axis represents the percent of patients improved, while the horizontal axis shows percent improvement in pain from baseline.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A line graph comparing percent improvement in pain from baseline versus percent of patients improved, showing two groups: Pregabalin 100 mg three times a day and placebo. The graph depicts that a higher percentage of patients improved with Pregabalin compared to placebo across various pain improvement thresholds.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line graph depicting the percent of patients improved plotted against percent improvement in pain from baseline. Four lines compare Pregabalin doses of 300 mg, 150 mg, 75 mg taken twice a day, and a placebo, showing varying degrees of pain improvement among groups.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph illustrates that higher doses of Pregabalin correlate with greater patient improvement compared to placebo.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The y-axis shows percent of patients improved (0 to 100%), and the x-axis shows percent improvement in pain from baseline (0 to 100%). Two vertical lines highlight specific improvement thresholds at approximately 30% and 50%.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

A bar chart showing responder rates (%) in two clinical studies labeled Study E1 and Study E3. The x-axis displays placebo and various daily doses of a drug (50 mg to 600 mg), while the y-axis shows responder rates from 0% to 60%. The data compares placebo against different doses, with annotations indicating statistical significance versus placebo.*

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

A line graph showing seizure reduction as median percentage change from baseline plotted against dose in mg/day for studies E1, E2, and E3 with BID and TID dosing schedules. The graph includes p-values indicating significance for seizure reduction at various doses compared to placebo.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

A line graph depicting the percent of patients improved on the y-axis against percent improvement in pain from baseline on the x-axis. The graph compares four groups: Pregabalin 600mg daily dose, 450mg daily dose, 300mg daily dose, and placebo, showing their respective trends in patient improvement percentages.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

A Kaplan-Meier survival curve comparing estimated percentage of subjects without LTR over 180 days between Pregabalin and Placebo groups. The y-axis represents the estimated percentage of subjects without LTR, and the x-axis represents the days. The Pregabalin group shows higher survival estimates than the Placebo group throughout the study period.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

A line graph comparing the percentage of subjects improved from baseline to Week 12 between Pregabalin and Placebo groups. The x-axis represents the percent improved, while the y-axis shows the percent of subjects improved. A solid line depicts Pregabalin, and a dotted line represents Placebo, indicating higher improvement rates with Pregabalin across improvement percentages.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

A line graph depicting the percent of subjects improved from baseline to Week 16 BOCF, comparing Pregabalin and Placebo. The x-axis shows the percent improvement from 0 to 100%, and the y-axis indicates the percent of subjects improved. Two lines represent the data: a solid line for Pregabalin and a dotted line for Placebo, showing higher improvement percentages for Pregabalin across most intervals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.